CClinicalTrials.gg
Status unknownNCT00487955A-P-REEUpdated Jun 19, 2007

The Metabolic Contribution of the Human Microbiota to Resting Energy Expenditure

An observational study in Gastritis, sponsored by Tel-Aviv Sourasky Medical Center. Status unknown at 1 site in Israel. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2007-06-19.

Sponsored by Tel-Aviv Sourasky Medical Center · Observational

The sponsor has not verified this record recently (last verified Mar 2007), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Defined population
Time perspective
Other
Enrollment
40
Ages
20 Years to 60 Years
Sex
All
01

Study summary

The purpose of our study is to evaluate the metabolic contribution of the human microbiota to resting energy expenditure

Read the detailed description

There are now >500 million adult humans in the world who are overweight [body mass index (BMI) of 25.0-29.9 kg/m2] and 250 million who are obese (BMI 30 kg/m2). This growing epidemic threatens both industrialized and developing countries and has been accompanied by worldwide increases in obesity-related disorders, including type II diabetes, hypertension, cardiovascular pathology, and nonalcoholic fatty liver disease. In the United States, 64% of adults are overweight or obese, prompting the Surgeon General to designate this condition as the most important public health challenge of our time.

The worldwide obesity epidemic is stimulating efforts to identify host and environmental factors that affect energy balance. The Human gut contains an immense number of microorganisms, collectively known as the microbiota. This community consists of at least 1013 citizens, is dominated by anaerobic bacteria, and includes 500-1,000 species whose collective genomes are estimated to contain 100 times more genes than our own human genome. The microbiota can be viewed as a metabolic "organ" exquisitely tuned to our physiology that performs functions that we have not had to evolve on our own. These functions include the ability to process otherwise indigestible components of our diet, such as plant polysaccharides, and therefore may have an impact on our energy balance.

Comparisons of the distal gut microbiota of genetically obese mice and their lean littermates, as well as those of obese and lean human volunteers have revealed that obesity is associated with changes in the relative abundance of two dominant bacterial divisions, the Bacteroidetes and the Firmicutes. Turnbaugh et al demonstrated through metagenomic and biochemical analyses that these changes affect the metabolic potential of the mouse gut microbiota. Furthermore, this trait is transmissible: colonization of germ-free mice with an 'obese microbiota' results in a significantly greater increase in total body fat than colonization with a 'lean microbiota'. These results identify the gut microbiota as an additional contributing factor to the pathophysiology of obesity. It has been suggested, therefore, that the obese microbiome has an increased capacity to harvest energy from the diet.

02

Conditions studied

  • Gastritis

Browse trials for

Keywords

  • gastritis
  • helicobacter pylori
  • REE
  • patients with gastritis that refers to helicobacter pylori treatment
03

In context

Gastritis

196 studies on the registry are indexed under Gastritis; 42 are open to participants now.

This study's planned enrollment of 40 is below the median of 400 across 79 observational studies indexed under Gastritis.

Browse Gastritis studies →

Lead sponsor

Tel-Aviv Sourasky Medical Center is the lead sponsor of 541 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 40 patients that refers to helicobacter pylori treatment
  • Aged 20-60 years old
  • 22 Kg/m2 ≤ BMI ≤ 30 Kg/m2
  • Functional GI trace with permanent stool number
  • Keeping on a permanent diet
  • Written informed consent
  • Stated availability throughout the study period
  • Mental ability to understand and follow the protocol

Exclusion criteria

Exclusion criteria

  • Use of laxatives
  • Confirmed GI tract infections or inflammatory bowel disease
  • Any major chronic illness
  • Pregnancy
  • Participation in other clinical trials
  • Use of oral or intravenous antibiotics during 8 weeks prior to recruitment
05

Study design

Observational model
Defined population
Time perspective
Other
Enrollment
40 participants (estimated)

Interventions

  • ProcedureResting Energy Expenditure examination
06

Study locations

1 of 1 sites recruiting
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 19, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00487955
Lead sponsor
Tel-Aviv Sourasky Medical Center
First posted
Jun 19, 2007
Start date
Jun 2007
Completion
Dec 2007 (estimated)
Last update
Jun 19, 2007

Study contacts

Nachum Vaisman, Prof.
Contact
vaisman@tasmc.health.gov.il
+972-524-266-596
Aharon Halak, Dr.
Contact
efratmo@tasmc.health.gov.il
+972-522-311-929
Nachum Vaisman, Prof.
study director

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion